NASDAQ:RXRX

Recursion Pharmaceuticals Stock Forecast, Price & News

$24.65
+0.25 (+1.02 %)
(As of 09/23/2021 12:00 AM ET)
Add
Compare
Today's Range
$23.60
$24.88
50-Day Range
$19.03
$35.99
52-Week Range
$17.80
$42.81
Volume283,097 shs
Average Volume482,805 shs
Market Capitalization$4.15 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive RXRX News and Ratings via Email

Sign-up to receive the latest news and ratings for Recursion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. It has four clinical-stage drug candidates focused on rare, monogenic diseases; and 33 additional programs in various stages of preclinical development. Recursion Pharmaceuticals, Inc. has strategic agreements with Bayer; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. The company was founded in 2013 and is based in Salt Lake City, Utah.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.75 out of 5 stars

Medical Sector

825th out of 1,351 stocks

Biological Products, Except Diagnostic Industry

123rd out of 193 stocks

Analyst Opinion: 3.3Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Recursion Pharmaceuticals (NASDAQ:RXRX) Frequently Asked Questions

Is Recursion Pharmaceuticals a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Recursion Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Recursion Pharmaceuticals stock.
View analyst ratings for Recursion Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Recursion Pharmaceuticals?

Wall Street analysts have given Recursion Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Recursion Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Recursion Pharmaceuticals' next earnings date?

Recursion Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, November 12th 2021.
View our earnings forecast for Recursion Pharmaceuticals
.

How were Recursion Pharmaceuticals' earnings last quarter?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) released its quarterly earnings data on Thursday, August, 12th. The company reported ($0.31) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.23) by $0.08.
View Recursion Pharmaceuticals' earnings history
.

What price target have analysts set for RXRX?

6 Wall Street analysts have issued 12-month target prices for Recursion Pharmaceuticals' shares. Their forecasts range from $30.00 to $37.00. On average, they expect Recursion Pharmaceuticals' stock price to reach $33.33 in the next twelve months. This suggests a possible upside of 35.2% from the stock's current price.
View analysts' price targets for Recursion Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Recursion Pharmaceuticals' key executives?

Recursion Pharmaceuticals' management team includes the following people:
  • Dr. Christopher C. Gibson, Co-Founder, CEO & Director (Age 38, Pay $315.79k)
  • Ms. Tina Marriott Larson, COO & Pres (Age 46, Pay $463.96k)
  • Dr. Dean Y. Li, Co-Founder & Independent Director (Age 59)
  • Dr. Blake C. Borgeson Ph.D., Co-Founder & Director (Age 39)
  • Dr. Michael Secora Ph.D., Chief Financial Officer (Age 38, Pay $320.86k)
  • Dr. Shafique Virani M.D., Chief Corp. Devel. Officer (Age 50, Pay $475.23k)
  • Dr. Ramona Doyle M.D., Chief Medical Officer (Age 62, Pay $3.67k)
  • Mr. Benjamin Mabey M.S., Chief Technology Officer (Age 38)
  • Dr. Sharathchandra S. Hegde, Chief Scientific Officer (Age 57)
  • Ms. Louisa Daniels J.D., M.B.A., Chief Legal Officer & Gen. Counsel (Age 63)

When did Recursion Pharmaceuticals IPO?

(RXRX) raised $306 million in an initial public offering (IPO) on Friday, April 16th 2021. The company issued 18,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, BofA Securities, SVB Leerink, Allen & Co. and KeyBanc Capital Markets served as the underwriters for the IPO.

What is Recursion Pharmaceuticals' stock symbol?

Recursion Pharmaceuticals trades on the NASDAQ under the ticker symbol "RXRX."

When does Recursion Pharmaceuticals' lock-up period expire?

Recursion Pharmaceuticals' lock-up period expires on Wednesday, October 13th. Recursion Pharmaceuticals had issued 24,242,424 shares in its initial public offering on April 16th. The total size of the offering was $436,363,632 based on an initial share price of $18.00. After the expiration of Recursion Pharmaceuticals' lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

Who are Recursion Pharmaceuticals' major shareholders?

Recursion Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (11.00%), Laurion Capital Management LP (2.29%), Vanguard Group Inc. (1.59%), ARK Investment Management LLC (1.41%), FMR LLC (1.31%) and Harvard Management Co. Inc. (0.90%).

Which institutional investors are buying Recursion Pharmaceuticals stock?

RXRX stock was bought by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Laurion Capital Management LP, Vanguard Group Inc., ARK Investment Management LLC, FMR LLC, Harvard Management Co. Inc., Credit Suisse AG, and BlackRock Inc..

How do I buy shares of Recursion Pharmaceuticals?

Shares of RXRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Recursion Pharmaceuticals' stock price today?

One share of RXRX stock can currently be purchased for approximately $24.65.

How much money does Recursion Pharmaceuticals make?

Recursion Pharmaceuticals has a market capitalization of $4.15 billion and generates $3.96 million in revenue each year.

How many employees does Recursion Pharmaceuticals have?

Recursion Pharmaceuticals employs 218 workers across the globe.

What is Recursion Pharmaceuticals' official website?

The official website for Recursion Pharmaceuticals is www.recursion.com.

Where are Recursion Pharmaceuticals' headquarters?

Recursion Pharmaceuticals is headquartered at 41S RIO GRANDE STREET, SALT LAKE CITY UT, 84101.

How can I contact Recursion Pharmaceuticals?

Recursion Pharmaceuticals' mailing address is 41S RIO GRANDE STREET, SALT LAKE CITY UT, 84101. The company can be reached via phone at 385-269-0203 or via email at [email protected].


This page was last updated on 9/24/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.